CompletedNot Applicable

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

Egypt96 participantsStarted 2020-05-01

Plain-language summary

There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to intravesical BCG therapy post trans-urethral resection of urinary bladder tumors for the non-invasive urinary bladder tumors.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Concomitant malignancy.
✕. Hematological disorders.
✕. History of radiation or chemotherapy.
✕. Concomitant infection or chronic inflammatory diseases.
✕. Missing preoperative differential blood cell count.
✕. Patients with low grade non muscle invasive Urinary baldder tumors.
✕. Patients missing BCG after biopsy revealing NMIBC.
✕. patients with non-compliance to BCG doses or the scheduled follow up.

What they're measuring

BCG failure

Timeframe: 3 years following tumor resection and BCG instillation

Trial details

NCT IDNCT05946369

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-01

View on ClinicalTrials.gov More Urinary Bladder Cancer trials